Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis.

PubWeight™: 0.91‹?›

🔗 View Article (PMID 25676470)

Published in J Infect Dis on February 12, 2015

Authors

Bryan T Mayer1, Sujatha Srinivasan1, Tina L Fiedler1, Jeanne M Marrazzo2, David N Fredricks3, Joshua T Schiffer4

Author Affiliations

1: Vaccine and Infectious Disease Division.
2: Department of Medicine.
3: Vaccine and Infectious Disease Division Clinical Research Division, Fred Hutchinson Cancer Research Center Department of Medicine Department of Microbiology, University of Washington, Seattle.
4: Vaccine and Infectious Disease Division Clinical Research Division, Fred Hutchinson Cancer Research Center Department of Medicine.

Articles cited by this

Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81

Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol (1991) 20.49

Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med (1983) 16.63

The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol (2008) 16.57

Decay characteristics of HIV-1-infected compartments during combination therapy. Nature (1997) 13.68

Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep (2006) 11.08

Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med (1995) 8.89

Reproducible community dynamics of the gastrointestinal microbiota following antibiotic perturbation. Infect Immun (2009) 7.48

Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis (1999) 6.85

High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis (2006) 5.96

Bacterial vaginosis and disturbances of vaginal flora: association with increased acquisition of HIV. AIDS (1998) 5.64

Temporal dynamics of the human vaginal microbiota. Sci Transl Med (2012) 4.58

Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36

The prevalence of bacterial vaginosis in the United States, 2001-2004; associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis (2007) 3.93

Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One (2010) 3.45

Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis (2003) 3.24

Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol (2007) 2.88

Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82

Bacterial communities in women with bacterial vaginosis: high resolution phylogenetic analyses reveal relationships of microbiota to clinical criteria. PLoS One (2012) 2.79

Temporal variability of human vaginal bacteria and relationship with bacterial vaginosis. PLoS One (2010) 2.62

Adherent biofilms in bacterial vaginosis. Obstet Gynecol (2005) 2.31

Changes in vaginal bacterial concentrations with intravaginal metronidazole therapy for bacterial vaginosis as assessed by quantitative PCR. J Clin Microbiol (2009) 2.29

Cultivation-independent analysis of changes in bacterial vaginosis flora following metronidazole treatment. J Clin Microbiol (2007) 2.06

Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics (2010) 2.04

Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis (2005) 2.04

An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am J Obstet Gynecol (2007) 2.04

Incidence of pelvic inflammatory disease after first-trimester legal abortion in women with bacterial vaginosis after treatment with metronidazole: a double-blind, randomized study. Am J Obstet Gynecol (1992) 2.02

Longitudinal analysis of the vaginal microflora in pregnancy suggests that L. crispatus promotes the stability of the normal vaginal microflora and that L. gasseri and/or L. iners are more conducive to the occurrence of abnormal vaginal microflora. BMC Microbiol (2009) 1.97

A cluster analysis of bacterial vaginosis-associated microflora and pelvic inflammatory disease. Am J Epidemiol (2005) 1.94

Vaginal microbiome: rethinking health and disease. Annu Rev Microbiol (2012) 1.94

Lower genital tract infection and endometritis: insight into subclinical pelvic inflammatory disease. Obstet Gynecol (2002) 1.85

Quantitative PCR assessments of bacterial species in women with and without bacterial vaginosis. J Clin Microbiol (2010) 1.69

Genital tract shedding of herpes simplex virus type 2 in women: effects of hormonal contraception, bacterial vaginosis, and vaginal group B Streptococcus colonization. Clin Infect Dis (2005) 1.60

Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother (1993) 1.52

Is it time for a metagenomic basis of therapeutics? Science (2012) 1.45

Longitudinal study of the dynamics of vaginal microflora during two consecutive menstrual cycles. PLoS One (2011) 1.06

Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis (1982) 1.06

The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment. Curr Opin Infect Dis (2013) 1.05

The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol (1996) 0.99

The microbiota of the human genitourinary tract: trying to see the forest through the trees. Trans Am Clin Climatol Assoc (2012) 0.98

Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. Antimicrob Agents Chemother (2013) 0.97

Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis (2014) 0.94

The genital econiche: focus on microbiota and bacterial vaginosis. Ann N Y Acad Sci (2011) 0.94

Mucosal HSV-2 Specific CD8+ T-Cells Represent Containment of Prior Viral Shedding Rather than a Correlate of Future Protection. Front Immunol (2013) 0.91

Implications of the human microbiome project for epidemiology. Am J Epidemiol (2013) 0.83

High-dose vaginal maintenance metronidazole for recurrent bacterial vaginosis: a pilot study. Sex Transm Dis (2014) 0.80

Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis (1992) 0.76

Molecular analysis of the relationship between specific vaginal bacteria and bacterial vaginosis metronidazole therapy failure. Eur J Clin Microbiol Infect Dis (2014) 0.76

Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis (1992) 0.76